DMP696 and DMP904: Two CRF1 Antagonists With Distinct Pharmacological Profiles for Anxiety
Two non-peptide CRF1 receptor antagonists (DMP696, DMP904) showed anxiolytic activity with distinct pharmacological profiles, advancing the CRF1 antagonist drug class for anxiety and depression treatment.
Quick Facts
What This Study Found
DMP696 and DMP904 demonstrated CRF1 receptor antagonist anxiolytic activity with distinct pharmacokinetic, selectivity, and efficacy profiles across anxiety models — advancing multiple CRF1 drug candidates with different clinical potential.
Key Numbers
How They Did This
review study on neuropeptides, anxiety-mood.
Why This Research Matters
Relevant for neuropeptides, anxiety-mood.
The Bigger Picture
Advances peptide research with clinical implications.
What This Study Doesn't Tell Us
See abstract.
Questions This Raises
- ?Further research needed.
- ?Clinical translation to evaluate.
Trust & Context
- Key Stat:
- Key finding DMP696 and DMP904 demonstrated CRF1 receptor antagonist anxiolytic activity with distinct pharmacokinetic, selectivity, and efficacy profiles across a
- Evidence Grade:
- moderate evidence.
- Study Age:
- Published in 2005.
- Original Title:
- The pharmacology of DMP696 and DMP904, non-peptidergic CRF1 receptor antagonists.
- Published In:
- CNS drug reviews, 11(1), 21-52 (2005)
- Authors:
- Li, Yu-Wen, Fitzgerald, Lawrence, Wong, Harvey, Lelas, Snjezana, Zhang, Ge, Lindner, Mark D, Wallace, Tanya, McElroy, John, Lodge, Nicholas J, Gilligan, Paul, Zaczek, Robert
- Database ID:
- RPEP-01065
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What was studied?
DMP696 and DMP904: Two CRF1 Antagonists With Distinct Pharmacological Profiles for Anxiety
What was found?
Two non-peptide CRF1 receptor antagonists (DMP696, DMP904) showed anxiolytic activity with distinct pharmacological profiles, advancing the CRF1 antagonist drug class for anxiety and depression treatment.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-01065APA
Li, Yu-Wen; Fitzgerald, Lawrence; Wong, Harvey; Lelas, Snjezana; Zhang, Ge; Lindner, Mark D; Wallace, Tanya; McElroy, John; Lodge, Nicholas J; Gilligan, Paul; Zaczek, Robert. (2005). The pharmacology of DMP696 and DMP904, non-peptidergic CRF1 receptor antagonists.. CNS drug reviews, 11(1), 21-52.
MLA
Li, Yu-Wen, et al. "The pharmacology of DMP696 and DMP904, non-peptidergic CRF1 receptor antagonists.." CNS drug reviews, 2005.
RethinkPeptides
RethinkPeptides Research Database. "The pharmacology of DMP696 and DMP904, non-peptidergic CRF1 ..." RPEP-01065. Retrieved from https://rethinkpeptides.com/research/li-2005-the-pharmacology-of-dmp696
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.